Mycn - v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Gene

Also Known as Nmyc; N-myc; Nmyc1; Nmyc-1; c-nmyc; bHLHe37

Species: Mus musculus

Gene Type: protein coding
Gene ID: 18109

Summary

Predicted to enable DNA-binding transcription activator activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and kinase binding activity. Involved in negative regulation of Reactive Oxygen Species metabolic process and positive regulation of transcription by RNA polymerase II. Acts upstream of or within several processes, including embryonic digit morphogenesis; negative regulation of astrocyte differentiation; and skeletal system morphogenesis. Located in nucleus. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; lung; and sensory organ. Human ortholog(s) of this gene implicated in Feingold syndrome. Orthologous to human MYCN (MYCN proto-oncogene, bHLH transcription factor). [provided by Alliance of Genome Resources, Apr 2022]

Mycn Products (1)

mRNA Protein Name
NM_008709.3 NP_032735.3 N-myc proto-oncogene protein

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables protein binding IPI
IPI: Inferred from physical interaction
10229200 MGI
Biological Process GO Annotation Evidence References Source
acts upstream of astrocyte differentiation IDA
IDA: Inferred from direct assay
18640244 MGI
acts upstream of positive effect autosome genomic imprinting IMP
IMP: Inferred from mutant phenotype
21047779 MGI
acts upstream of or within branching morphogenesis of an epithelial tube IMP
IMP: Inferred from mutant phenotype
15716345 MGI
acts upstream of or within cartilage condensation IMP
IMP: Inferred from mutant phenotype
17360777 MGI
acts upstream of cell population proliferation IMP
IMP: Inferred from mutant phenotype
15716345 MGI
acts upstream of or within embryonic digit morphogenesis IMP
IMP: Inferred from mutant phenotype
17360777 MGI
acts upstream of or within embryonic skeletal system morphogenesis IMP
IMP: Inferred from mutant phenotype
17360777 MGI
acts upstream of epithelial cell proliferation IMP
IMP: Inferred from mutant phenotype
15716345 MGI
acts upstream of or within lung development IMP
IMP: Inferred from mutant phenotype
15716345 MGI
acts upstream of or within negative regulation of astrocyte differentiation IDA
IDA: Inferred from direct assay
18640244 MGI
involved in negative regulation of reactive oxygen species metabolic process IDA
IDA: Inferred from direct assay
17357786 MGI
involved in positive regulation of DNA-templated transcription IDA
IDA: Inferred from direct assay
17357786 MGI
acts upstream of or within positive regulation of epithelial cell proliferation IMP
IMP: Inferred from mutant phenotype
15716345 MGI
acts upstream of or within positive regulation of mesenchymal cell proliferation IMP
IMP: Inferred from mutant phenotype
17360777 MGI
acts upstream of or within positive regulation of programmed cell death IMP
IMP: Inferred from mutant phenotype
17360777 MGI
involved in positive regulation of transcription by RNA polymerase II IMP
IMP: Inferred from mutant phenotype
21047779 MGI
acts upstream of or within regulation of inner ear auditory receptor cell differentiation IGI
IGI: Inferred from genetic interaction
23022312 MGI
Cellular Component GO Annotation Evidence References Source
located in nucleus IDA
IDA: Inferred from direct assay
15716345 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

N-myc proto-oncogene protein

  • neuroblastoma myc-related oncogene 1

  • v-myc myelocytomatosis viral related oncogene, neuroblastoma derived

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-11103 Sitaxsentan sodium 98.83% Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-117286 (S)-JQ-35 99.46% Phase 1

Pre-clinical Phase

Bioactive Molecules (21)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-145765 JQAD1 98.24% Unkown
HY-156443 YG1702 Inhibitor 99.94% Unkown
HY-124447 BTYNB 98.0% Unkown
HY-112273 CD532 Inhibitor 98.86% Unkown
HY-144878 VPC-70619 Inhibitor 99.93% Unkown
HY-171767 SK2188 99.87% Unkown
HY-171768 SK2187 Degrader 95.81% Unkown
HY-168439 HLB-0532259 Degrader 98.30% Unkown
HY-112273A CD532 hydrochloride Inhibitor 99.62% Unkown
HY-171769 dAurAB2 Degrader / Unkown
HY-158062 LC-1-40 / Unkown
HY-152032 LSD1-IN-23 Inhibitor / Unkown
HY-179375 LCI133 Inhibitor / Unkown
HY-179640 SK4454 Degrader / Unkown
HY-179641 SK5527 Degrader / Unkown
HY-181442 CK2-TN03 98.02% Unkown
HY-181601 NPD15261 Inducer / Unkown
HY-RS08884 MYCN Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-181568 PROTAC Aurora A Degrader-1 / Unkown
HY-RS17293 Mycn Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23748 Mycn Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Mycn NCBI NCBI:4613